Skip to main content
. 2022 May 30;117(6):1479–1492. doi: 10.1111/mmi.14920

FIGURE 3.

FIGURE 3

The C‐terminal PfbB SSURE domain binds to collagens and C1q. (a) Inhibition of binding of D39 pneumococci to collagens after bacterial pretreatment with serum raised in mice against recombinant PfbB C‐SSURE (anti‐SSURE serum). Serum from unimmunized mice (Normal serum) was used as a control. Bacterial binding was detected by counting colony‐forming units (CFU) after detachment of bacteria with trypsin. (b) Binding of histidine (his)‐tagged recombinant PfbB C‐SSURE to collagens and complement components. Binding was detected by ELISA using an anti‐his antibody. Plates were sensitized with 5 μg/ml of collagen types I, II, III, IV, VI, complement protein 1q (C1q), complement protein 3 (C3), factor B, factor H, factor I or bovine serum albumin (BSA), used as control. (c and d) Dose‐dependent binding of N‐SSURE (c) and C‐SSURE (d) domains to wells sensitized with 1 μg/ml of collagen type I, II, III, IV, VI and complement protein 1q (C1q). The binding of increasing concentrations of recombinant proteins fused to histidine (his) was revealed by ELISA using an anti‐his antibody. Shown are means ± SDs of three independent experiments conducted in triplicate.